Skip to main content
Erschienen in: Metabolic Brain Disease 1/2019

22.11.2018 | Original Article

Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia

verfasst von: Buranee Kanchanatawan, Sira Sriswasdi, Michael Maes

Erschienen in: Metabolic Brain Disease | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Stable phase schizophrenia is characterized by altered patterning in tryptophan catabolites (TRYCATs) and memory impairments, which are associated with PHEMN (psychosis, hostility, excitation, mannerism and negative) and DAPS (depression, anxiety and physio-somatic) symptoms. This study was carried out to examine the association between TRYCAT patterning, memory impairments, psychopathological features and health-related quality of life (HR-QoL) in schizophrenia. The World Health Organization (WHO) QoL instrument-Abbreviated version (WHO-QoL-BREF), IgA/IgM responses to TRYCATs, cognitive tests, Scale for the Assessment of Negative Symptoms (SANS), Hamilton and Depression (HAMD) and Anxiety (HAMA) Rating Scales and the Fibromyalgia and Chronic Fatigue Syndrome Rating Scale (FF) were measured in 80 schizophrenia patients and 40 controls. Neural Network analysis shows that the total HR-Qol score is best predicted by (in descending order) HAMA, FF, HAMD, and psychosis. Partial least Squares (PLS) analysis shows that 56.7% of the variance in the WHO-QoL scores is explained by PHEMN / DAPS symptoms, while 64.3% of the variance in those symptoms is explained by TRYCAT patterning and episodic/semantic memory impairments. IgA responses to picolinic acid, xanthurenic acid and 3-hydroxy-kynurenine (all negatively) and anthranilic acid (positively) have highly significant indirect effects on WHO-QoL scores, which are completely mediated by cognitive impairments and PHEMN / DAPS symptoms. The results show that lowered HR-Qol in schizophrenia is strongly associated with noxious TRYCATs and that these effects are mediated by impairments in episodic / semantic memory and schizophrenia phenomenology, especially physio-somatic and anxiety symptoms. Mucosal activation of the TRYCAT pathway combined with a deficit in natural IgM isotype antibodies to TRYCATs determine cognitive impairments and DAPS/PHEMN symptoms, which together determine to a large extent lowered HR-QoL in schizophrenia.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Abadi M, Agarwal, A, Barham, P, Brevdo, E, Chen, Z, Citro, C, Corrado, G S, Davis, A, Dean J, Devin, M, Ghemawat, S, Goodfellow, I, Harp, A, Irving, G, Isard, M, Jozefowicz, R, Jia, Y, Kaiser, L, Kudlur, M, Levenburg, J, Mane, D, Schuster, M, Monga, R, Moore, S, Murray, D, Olah, C, Shlens, J, Steiner, B, Sutskever, I, Talwar, K, Tucker, P, Vahoucke, V, Vasudevan, C, Viegas, F, Vinyals, O, Warden, P, Wattenerg, M, Wicke, M, Yu, Y, and Zheng, X (2015). TensorFlow: large-scale machine learning on heterogenous systems. Software available from tensorflow.org. Abadi M, Agarwal, A, Barham, P, Brevdo, E, Chen, Z, Citro, C, Corrado, G S, Davis, A, Dean J, Devin, M, Ghemawat, S, Goodfellow, I, Harp, A, Irving, G, Isard, M, Jozefowicz, R, Jia, Y, Kaiser, L, Kudlur, M, Levenburg, J, Mane, D, Schuster, M, Monga, R, Moore, S, Murray, D, Olah, C, Shlens, J, Steiner, B, Sutskever, I, Talwar, K, Tucker, P, Vahoucke, V, Vasudevan, C, Viegas, F, Vinyals, O, Warden, P, Wattenerg, M, Wicke, M, Yu, Y, and Zheng, X (2015). TensorFlow: large-scale machine learning on heterogenous systems. Software available from tensorflow.​org.
Zurück zum Zitat Alptekin K, Akvardar Y, Kivircik Akdede BB, Dumlu K, Işik D, Pirinçci F, Yahssin S, Kitiş A (2005). Is quality of life associated with cognitive impairment in schizophrenia? Prog Neuro-Psychopharmacol Biol Psychiatry 29(2):239–244. Epub 2004 Dec 23. PubMed PMID: 15694230. Alptekin K, Akvardar Y, Kivircik Akdede BB, Dumlu K, Işik D, Pirinçci F, Yahssin S, Kitiş A (2005). Is quality of life associated with cognitive impairment in schizophrenia? Prog Neuro-Psychopharmacol Biol Psychiatry 29(2):239–244. Epub 2004 Dec 23. PubMed PMID: 15694230.
Zurück zum Zitat Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell'osso B, Kanba S, Monji A, Fatemi SH, Buckley P, Debnath M, Das UN, Meyer U, Müller N, Kanchanatawan B, Maes M (2013) Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 42:1–4. https://doi.org/10.1016/j.pnpbp.2012.10.008. Epub 2012 Oct 18. PubMed PMID: 23085074. Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell'osso B, Kanba S, Monji A, Fatemi SH, Buckley P, Debnath M, Das UN, Meyer U, Müller N, Kanchanatawan B, Maes M (2013) Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 42:1–4. https://​doi.​org/​10.​1016/​j.​pnpbp.​2012.​10.​008. Epub 2012 Oct 18. PubMed PMID: 23085074.
Zurück zum Zitat Anderson G, Maes M (2013) Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 42: 5–19. https://doi.org/10.1016/j.pnpbp.2012.06.014. Epub 2012 Jul 16. Review. PubMed PMID: 22800757. Anderson G, Maes M (2013) Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 42: 5–19. https://​doi.​org/​10.​1016/​j.​pnpbp.​2012.​06.​014. Epub 2012 Jul 16. Review. PubMed PMID: 22800757.
Zurück zum Zitat Andreasen NC (1989) The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 7:49–58CrossRef Andreasen NC (1989) The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 7:49–58CrossRef
Zurück zum Zitat Becker T, Leese M, Krumm S, Ruggeri M, Vázquez-Barquero JL, EPSILON Study Group (2005) Needs and quality of life among patients with schizophrenia in five European centres: what is the impact of global functioning scores? Soc Psychiatry Psychiatr Epidemiol 40(8):628–634CrossRef Becker T, Leese M, Krumm S, Ruggeri M, Vázquez-Barquero JL, EPSILON Study Group (2005) Needs and quality of life among patients with schizophrenia in five European centres: what is the impact of global functioning scores? Soc Psychiatry Psychiatr Epidemiol 40(8):628–634CrossRef
Zurück zum Zitat Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistics Society Series b (Methodological) 57:289–300CrossRef Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistics Society Series b (Methodological) 57:289–300CrossRef
Zurück zum Zitat Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, Yung AR, Anderson VA, McGorry PD (2005) Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry 162(1): 71–78. PubMed PMID: 15625204. Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, Yung AR, Anderson VA, McGorry PD (2005) Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry 162(1): 71–78. PubMed PMID: 15625204.
Zurück zum Zitat Brinholi FF, Noto C, Maes M, Bonifácio KL, Brietzke E, Ota VK, Gadelha A, Cordeiro Q, Belangero SI, Bressan RA, Vargas HO, Higachi L, de Farias CC, Moreira EG, Barbosa DS (2015) Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naïve first episode psychosis. Schizophr Res 166(1–3):225–230. https://doi.org/10.1016/j.schres.2015.06.009. Epub 2015 Jun 27. PubMed PMID: 26123170. Brinholi FF, Noto C, Maes M, Bonifácio KL, Brietzke E, Ota VK, Gadelha A, Cordeiro Q, Belangero SI, Bressan RA, Vargas HO, Higachi L, de Farias CC, Moreira EG, Barbosa DS (2015) Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naïve first episode psychosis. Schizophr Res 166(1–3):225–230. https://​doi.​org/​10.​1016/​j.​schres.​2015.​06.​009. Epub 2015 Jun 27. PubMed PMID: 26123170.
Zurück zum Zitat Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bousoño M (2007) Quality of life in schizophrenic patients. Dialogues Clin Neurosci 9(2):215–226. Review.PubMed PMID: 17726919; PubMed Central PMCID: PMC3181847. Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bousoño M (2007) Quality of life in schizophrenic patients. Dialogues Clin Neurosci 9(2):215–226. Review.PubMed PMID: 17726919; PubMed Central PMCID: PMC3181847.
Zurück zum Zitat Cardoso CS, Caiaffa WT, Bandeira M, Siqueira AL, Abreu MN, Fonseca JO (2005) Factors associated with low quality of life in schizophrenia. Cad Saude Publica 21(5): 1338–1340. Epub 2005 Sep 12. PubMed PMID: 16158138. Cardoso CS, Caiaffa WT, Bandeira M, Siqueira AL, Abreu MN, Fonseca JO (2005) Factors associated with low quality of life in schizophrenia. Cad Saude Publica 21(5): 1338–1340. Epub 2005 Sep 12. PubMed PMID: 16158138.
Zurück zum Zitat Cepeda-carrion GA, Nitzl C, Roldan JL (2018) Mediation analyses in partial least squares structural equation modeling: guidelines and empirical examples. Chapter 9. Partial least squares structural equation modeling: basic concepts, methodological issues and applications, editors: Latan H, Noonan R. Springer, Heidelberg, pp 173–195. https://doi.org/10.1007/978-3-319-64069-3_8 Cepeda-carrion GA, Nitzl C, Roldan JL (2018) Mediation analyses in partial least squares structural equation modeling: guidelines and empirical examples. Chapter 9. Partial least squares structural equation modeling: basic concepts, methodological issues and applications, editors: Latan H, Noonan R. Springer, Heidelberg, pp 173–195. https://​doi.​org/​10.​1007/​978-3-319-64069-3_​8
Zurück zum Zitat Corlett PR, Murray GK, Honey GD, Aitken MR, Shanks DR, Robbins TW, Bullmore ET, Dickinson A, Fletcher PC (2007) Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. Brain 130(Pt 9):2387–2400. Epub 2007 Aug 9. PubMed PMID: 17690132; PubMed Central PMCID: PMC3838942 Corlett PR, Murray GK, Honey GD, Aitken MR, Shanks DR, Robbins TW, Bullmore ET, Dickinson A, Fletcher PC (2007) Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. Brain 130(Pt 9):2387–2400. Epub 2007 Aug 9. PubMed PMID: 17690132; PubMed Central PMCID: PMC3838942
Zurück zum Zitat Davis J, Moylan S, Harvey BH, Maes M, Berk M (2014) Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. Aust N Z J Psychiatry 48(6):512–529. https://doi.org/10.1177/0004867414533012. Epub 2014 May 6. Review. PubMed PMID: 24803587. Davis J, Moylan S, Harvey BH, Maes M, Berk M (2014) Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. Aust N Z J Psychiatry 48(6):512–529. https://​doi.​org/​10.​1177/​0004867414533012​. Epub 2014 May 6. Review. PubMed PMID: 24803587.
Zurück zum Zitat Davis J, Eyre H, Jacka FN, Dodd S, Dean O, McEwen S, Debnath M, McGrath J, Maes M, Amminger P, McGorry PD, Pantelis C, Berk M (2016) A review of vulnerability and risks for schizophrenia: beyond the two hit hypothesis. Neurosci Biobehav Rev 65:185–194. https://doi.org/10.1016/j.neubiorev.2016.03.017. Epub 2016 Apr 9. Review. PubMed PMID: 27073049; PubMed Central PMCID: PMC4876729. Davis J, Eyre H, Jacka FN, Dodd S, Dean O, McEwen S, Debnath M, McGrath J, Maes M, Amminger P, McGorry PD, Pantelis C, Berk M (2016) A review of vulnerability and risks for schizophrenia: beyond the two hit hypothesis. Neurosci Biobehav Rev 65:185–194. https://​doi.​org/​10.​1016/​j.​neubiorev.​2016.​03.​017. Epub 2016 Apr 9. Review. PubMed PMID: 27073049; PubMed Central PMCID: PMC4876729.
Zurück zum Zitat Falk Hvidberg M, Brinth LS, Olesen AV, Petersen KD, Ehlers L (2015) The health-related quality of life for patients with Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). PLoS One 10(7):e0132421. https://doi.org/10.1371/journal.pone.0132421. eCollection 2015. PubMed PMID: 26147503; PubMed Central PMCID: PMC4492975. Falk Hvidberg M, Brinth LS, Olesen AV, Petersen KD, Ehlers L (2015) The health-related quality of life for patients with Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). PLoS One 10(7):e0132421. https://​doi.​org/​10.​1371/​journal.​pone.​0132421. eCollection 2015. PubMed PMID: 26147503; PubMed Central PMCID: PMC4492975.
Zurück zum Zitat Fitzgerald PB, Williams CL, Corteling N, Filia SL, Brewer K, Adams A, de Castella AR, Rolfe T, Davey P, Kulkarni J (2001) Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand 103(5):387–392CrossRef Fitzgerald PB, Williams CL, Corteling N, Filia SL, Brewer K, Adams A, de Castella AR, Rolfe T, Davey P, Kulkarni J (2001) Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand 103(5):387–392CrossRef
Zurück zum Zitat Frith CD, Blakemore S, Wolpert DM (2000) Explaining the symptoms of schizophrenia: abnormalities in the awareness of action. Brain Res Brain Res Rev 31(2–3):357–363CrossRef Frith CD, Blakemore S, Wolpert DM (2000) Explaining the symptoms of schizophrenia: abnormalities in the awareness of action. Brain Res Brain Res Rev 31(2–3):357–363CrossRef
Zurück zum Zitat Górna K, Jaracz K, Jaracz J, Kiejda J, Grabowska-Fudala B, Rybakowski J (2014) [Social functioning and quality of life in schizophrenia patients --relationship with symptomatic remission and duration of illness]. Psychiatr Pol 48(2):277–288. Polish. PubMed PMID: 25016765. Górna K, Jaracz K, Jaracz J, Kiejda J, Grabowska-Fudala B, Rybakowski J (2014) [Social functioning and quality of life in schizophrenia patients --relationship with symptomatic remission and duration of illness]. Psychiatr Pol 48(2):277–288. Polish. PubMed PMID: 25016765.
Zurück zum Zitat Häfner H (2003) Gender differences in schizophrenia. Psychoneuroendocrinology 2:17–54CrossRef Häfner H (2003) Gender differences in schizophrenia. Psychoneuroendocrinology 2:17–54CrossRef
Zurück zum Zitat Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55CrossRef Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55CrossRef
Zurück zum Zitat Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62CrossRef Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62CrossRef
Zurück zum Zitat Harvey PD, Koren D, Reihenberg A, Bowie CR (2006) Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull 32:250–258CrossRef Harvey PD, Koren D, Reihenberg A, Bowie CR (2006) Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull 32:250–258CrossRef
Zurück zum Zitat Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH (2004) Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr Res 67(2–3):115–122. PubMed PMID: 14984870. Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH (2004) Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr Res 67(2–3):115–122. PubMed PMID: 14984870.
Zurück zum Zitat Kanchanatawan B, Hemrungrojn S, Thika S, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Maes M (2018a) Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia. Mol Neurobiol https://doi.org/10.1007/s12035-017-0751-8. [Epub ahead of print] PubMed PMID: 28875464. Kanchanatawan B, Hemrungrojn S, Thika S, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Maes M (2018a) Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia. Mol Neurobiol https://​doi.​org/​10.​1007/​s12035-017-0751-8. [Epub ahead of print] PubMed PMID: 28875464.
Zurück zum Zitat Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Maes M (2018b) Deficit schizophrenia is characterized by defects in IgM-mediated responses to tryptophan catabolites (TRYCATs): a paradigm shift towards defects in natural self-regulatory immune responses coupled with mucosa-derived TRYCAT pathway activation. Mol Neurobiol 55(3):2214–2226. https://doi.org/10.1007/s12035-017-0465-y. Epub 2017 Mar 14. PubMed PMID: 28290151 Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Maes M (2018b) Deficit schizophrenia is characterized by defects in IgM-mediated responses to tryptophan catabolites (TRYCATs): a paradigm shift towards defects in natural self-regulatory immune responses coupled with mucosa-derived TRYCAT pathway activation. Mol Neurobiol 55(3):2214–2226. https://​doi.​org/​10.​1007/​s12035-017-0465-y. Epub 2017 Mar 14. PubMed PMID: 28290151
Zurück zum Zitat Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Ormstad H, Anderson G, Maes M (2018c) Deficit, but not nondeficit, schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway with highly specific increases in IgA responses directed to Picolinic, Xanthurenic, and Quinolinic acid. Mol Neurobiol 55(2):1524–1536. https://doi.org/10.1007/s12035-017-0417-6. Epub 2017 Feb 8. PubMed PMID: 28181189 Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Ormstad H, Anderson G, Maes M (2018c) Deficit, but not nondeficit, schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway with highly specific increases in IgA responses directed to Picolinic, Xanthurenic, and Quinolinic acid. Mol Neurobiol 55(2):1524–1536. https://​doi.​org/​10.​1007/​s12035-017-0417-6. Epub 2017 Feb 8. PubMed PMID: 28181189
Zurück zum Zitat Kanchanatawan B, Sriswasdi S, Thika S, Sirivichayakul S, Carvalho AF, Geffard M, Kubera M., Maes M (2018d) Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: results of supervised Mach Learn Metab Brain Dis https://doi.org/10.1007/s11011-018-0208-4.[Epub ahead of print] PubMed PMID: 29527624. Kanchanatawan B, Sriswasdi S, Thika S, Sirivichayakul S, Carvalho AF, Geffard M, Kubera M., Maes M (2018d) Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: results of supervised Mach Learn Metab Brain Dis https://​doi.​org/​10.​1007/​s11011-018-0208-4.[Epub ahead of print] PubMed PMID: 29527624.
Zurück zum Zitat Kanchanatawan, B, Thika S, Sirivichayakul S, Carvalho AF, Geffard M, Maes M (2018e) In schizophrenia, depression, anxiety, and Physiosomatic symptoms are strongly related to psychotic symptoms and excitation, impairments in episodic memory, and increased production of neurotoxic tryptophan catabolites: a multivariate and machine learning study. Neurotox Res 33(3):641–655. https://doi.org/10.1007/s12640-018-9868-4. Epub 2018 Jan 29. PubMed PMID: 29380275. Kanchanatawan, B, Thika S, Sirivichayakul S, Carvalho AF, Geffard M, Maes M (2018e) In schizophrenia, depression, anxiety, and Physiosomatic symptoms are strongly related to psychotic symptoms and excitation, impairments in episodic memory, and increased production of neurotoxic tryptophan catabolites: a multivariate and machine learning study. Neurotox Res 33(3):641–655. https://​doi.​org/​10.​1007/​s12640-018-9868-4. Epub 2018 Jan 29. PubMed PMID: 29380275.
Zurück zum Zitat Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276CrossRef Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276CrossRef
Zurück zum Zitat Keefe RS, Harvey PD (2012) Cognitive impairment in schizophrenia. Handb Exp Pharmacol 213:11–37CrossRef Keefe RS, Harvey PD (2012) Cognitive impairment in schizophrenia. Handb Exp Pharmacol 213:11–37CrossRef
Zurück zum Zitat Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr (1989) The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30:119–123CrossRef Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr (1989) The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30:119–123CrossRef
Zurück zum Zitat Kita T, Morrison PF, Heyes MP, Markey SP (2002) Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the L-kynurenine and quinolinic acid pools in brain. J Neurochem 82(2):258–268CrossRef Kita T, Morrison PF, Heyes MP, Markey SP (2002) Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the L-kynurenine and quinolinic acid pools in brain. J Neurochem 82(2):258–268CrossRef
Zurück zum Zitat Kittirathanapaiboon P, Khamwongpin M (2005) The validity of the mini international neuropsychiatric interview (M.I.N.I.) Thai version: Suanprung hospital, department of Mental Health, 125–131. Kittirathanapaiboon P, Khamwongpin M (2005) The validity of the mini international neuropsychiatric interview (M.I.N.I.) Thai version: Suanprung hospital, department of Mental Health, 125–131.
Zurück zum Zitat Leung A, Chue P (2000) Sex differences in schizophrenia. a review of the literature Acta Psychiatr Scand Suppl 401:3–38CrossRef Leung A, Chue P (2000) Sex differences in schizophrenia. a review of the literature Acta Psychiatr Scand Suppl 401:3–38CrossRef
Zurück zum Zitat Lobo V, Patil A, Phatak A, Chandra N (2010) Free radicals, antioxidants and functional foods: impact on human health. Pharmacogn Rev 4(8):118–126CrossRef Lobo V, Patil A, Phatak A, Chandra N (2010) Free radicals, antioxidants and functional foods: impact on human health. Pharmacogn Rev 4(8):118–126CrossRef
Zurück zum Zitat Lowry PB, Gaskin J (2014) Partial least squares (PLS) structural equation modeling (SEM) for building and testing behavioral causal theory: when to choose it and how to use it. IEEE Transactions on Prof Comm 57(2):123–146CrossRef Lowry PB, Gaskin J (2014) Partial least squares (PLS) structural equation modeling (SEM) for building and testing behavioral causal theory: when to choose it and how to use it. IEEE Transactions on Prof Comm 57(2):123–146CrossRef
Zurück zum Zitat Maes M, Meltzer HY, Bosmans E (1994) Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89(5):346–351. PubMed PMID: 8067274. Maes M, Meltzer HY, Bosmans E (1994) Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89(5):346–351. PubMed PMID: 8067274.
Zurück zum Zitat Maes M, Meltzer HY, Buckley P, Bosmans E (1995b) Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 244(6):325–329. PubMed PMID: 7772617. Maes M, Meltzer HY, Buckley P, Bosmans E (1995b) Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 244(6):325–329. PubMed PMID: 7772617.
Zurück zum Zitat Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY (1995a) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29(2):141–152. PubMed PMID: 7666381. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY (1995a) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29(2):141–152. PubMed PMID: 7666381.
Zurück zum Zitat Maes M, Landucci Bonifacio K, Vargas HO, Barbosa DS, Carvalho AF, Vargas Nunes SO (2018) Major differences in neuro-oxidative and neuro-nitrosative stress pathways between major depressive disorder and types I and II bipolar disorders. Mol Neurobiol 2018, in press. Maes M, Landucci Bonifacio K, Vargas HO, Barbosa DS, Carvalho AF, Vargas Nunes SO (2018) Major differences in neuro-oxidative and neuro-nitrosative stress pathways between major depressive disorder and types I and II bipolar disorders. Mol Neurobiol 2018, in press.
Zurück zum Zitat McGurk SR, Mueser KT (2003) Cognitive functioning and employment in severe mental illness. J Nerv Ment Dis 191(12):789–798. PubMed PMID: 14671455. McGurk SR, Mueser KT (2003) Cognitive functioning and employment in severe mental illness. J Nerv Ment Dis 191(12):789–798. PubMed PMID: 14671455.
Zurück zum Zitat Moylan S, Eyre HA, Maes M, Baune BT, Jacka FN, Berk M (2013) Exercising the worry away: how inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours. Neurosci Biobehav Rev 37(4):573–584CrossRef Moylan S, Eyre HA, Maes M, Baune BT, Jacka FN, Berk M (2013) Exercising the worry away: how inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours. Neurosci Biobehav Rev 37(4):573–584CrossRef
Zurück zum Zitat Myhre SR (2015) False memories in depression: vulnerability factor or symptom? Thesis, North Dakota State University of Agriculture and Applied Science Fargo, North Dakota Myhre SR (2015) False memories in depression: vulnerability factor or symptom? Thesis, North Dakota State University of Agriculture and Applied Science Fargo, North Dakota
Zurück zum Zitat Norman RM, Malla AK, McLean T, Voruganti LP, Cortese L, McIntosh E, Cheng S, Rickwood A (2000) The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the quality of life scale. Acta Psychiatr Scand 102(4):303–309CrossRef Norman RM, Malla AK, McLean T, Voruganti LP, Cortese L, McIntosh E, Cheng S, Rickwood A (2000) The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the quality of life scale. Acta Psychiatr Scand 102(4):303–309CrossRef
Zurück zum Zitat Noto C, Ota VK, Santoro ML, Gouvea ES, Silva PN, Spindola LM, Cordeiro Q, Bressan RA, Gadelha A, Brietzke E, Belangero SI, Maes M (2016) Depression, cytokine, and cytokine by treatment interactions modulate gene expression in antipsychotic Naïve first episode psychosis. Mol Neurobiol 53(8):5701–5709. https://doi.org/10.1007/s12035-015-9489-3. Epub 2015 Oct 22. PubMed PMID: 26491028. Noto C, Ota VK, Santoro ML, Gouvea ES, Silva PN, Spindola LM, Cordeiro Q, Bressan RA, Gadelha A, Brietzke E, Belangero SI, Maes M (2016) Depression, cytokine, and cytokine by treatment interactions modulate gene expression in antipsychotic Naïve first episode psychosis. Mol Neurobiol 53(8):5701–5709. https://​doi.​org/​10.​1007/​s12035-015-9489-3. Epub 2015 Oct 22. PubMed PMID: 26491028.
Zurück zum Zitat Noto C, Maes M, Ota VK, Teixeira AL, Bressan RA, Gadelha A, Brietzke E (2015a) High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. World J Biol Psychiatry 27:1–8. [Epub ahead of print] PubMed PMID: 26212792. Noto C, Maes M, Ota VK, Teixeira AL, Bressan RA, Gadelha A, Brietzke E (2015a) High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. World J Biol Psychiatry 27:1–8. [Epub ahead of print] PubMed PMID: 26212792.
Zurück zum Zitat Noto C, Ota VK, Gadelha A, Noto MN, Barbosa DS, Bonifácio KL, Nunes SO, Cordeiro Q, Belangero SI, Bressan RA, Maes M, Brietzke E (2015b) Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone. J Psychiatr Res 68, 210–216. https://doi.org/10.1016/j.jpsychires.2015.07.003. Epub 2015 Jul 3. PubMed PMID: 26228421. Noto C, Ota VK, Gadelha A, Noto MN, Barbosa DS, Bonifácio KL, Nunes SO, Cordeiro Q, Belangero SI, Bressan RA, Maes M, Brietzke E (2015b) Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone. J Psychiatr Res 68, 210–216. https://​doi.​org/​10.​1016/​j.​jpsychires.​2015.​07.​003. Epub 2015 Jul 3. PubMed PMID: 26228421.
Zurück zum Zitat Orellana G, Slachevsky A (2013) Executive functioning in schizophrenia. Front Psychiatry. 4:35CrossRef Orellana G, Slachevsky A (2013) Executive functioning in schizophrenia. Front Psychiatry. 4:35CrossRef
Zurück zum Zitat Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psycholog Rep 10:799–812CrossRef Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psycholog Rep 10:799–812CrossRef
Zurück zum Zitat Richards M, Sacker A (2003) Lifetime antecedents of cognitive reserve. J Clin Exp Neuropsychol 25(5):614–624CrossRef Richards M, Sacker A (2003) Lifetime antecedents of cognitive reserve. J Clin Exp Neuropsychol 25(5):614–624CrossRef
Zurück zum Zitat Ringle CM, da Silva D, Bido D (2014) Structural equation modeling with the SmartPLS. Brazilian Journal of Marketing - BJM Revista Brasileira de Marketing – ReMark Edição Especial 13(2) Ringle CM, da Silva D, Bido D (2014) Structural equation modeling with the SmartPLS. Brazilian Journal of Marketing - BJM Revista Brasileira de Marketing – ReMark Edição Especial 13(2)
Zurück zum Zitat Ritsner M, Kurs, R, Gibel A, Ratner Y, Endicott J (2005) Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res 14(7):1693–1703. PubMed PMID: 16119181. Ritsner M, Kurs, R, Gibel A, Ratner Y, Endicott J (2005) Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res 14(7):1693–1703. PubMed PMID: 16119181.
Zurück zum Zitat Savill M, Orfanos S, Reininghaus U, Wykes T, Bentall R, Priebe S (2016) The relationship between experiential deficits of negative symptoms and subjective quality of life in schizophrenia. Schizophr Res 176(2–3):387–391CrossRef Savill M, Orfanos S, Reininghaus U, Wykes T, Bentall R, Priebe S (2016) The relationship between experiential deficits of negative symptoms and subjective quality of life in schizophrenia. Schizophr Res 176(2–3):387–391CrossRef
Zurück zum Zitat Schweitzer R, Kelly B, Foran A, Terry D, Whiting J (1995) Quality of life in chronic fatigue syndrome. Soc Sci Med 41(10):1367–1372. PubMed PMID: 8560304 Schweitzer R, Kelly B, Foran A, Terry D, Whiting J (1995) Quality of life in chronic fatigue syndrome. Soc Sci Med 41(10):1367–1372. PubMed PMID: 8560304
Zurück zum Zitat Sim K, Mahendran R, Siris SG, Heckers S, Chong SA (2004) Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res 129(2):141–147. PubMed PMID: 15590041. Sim K, Mahendran R, Siris SG, Heckers S, Chong SA (2004) Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res 129(2):141–147. PubMed PMID: 15590041.
Zurück zum Zitat Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho AF, Maes M. (2018) Eotaxin, an endogenous cognitive deteriorating chemokine (ECDC), is a major contributor to cognitive decline in Normal people and to executive, memory, and sustained attention deficits, formal thought disorders, and psychopathology in schizophrenia patients. Neurotox Res. https://doi.org/10.1007/s12640-018-9937-8. [Epub ahead of print] PubMed PMID: 30056534. Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho AF, Maes M. (2018) Eotaxin, an endogenous cognitive deteriorating chemokine (ECDC), is a major contributor to cognitive decline in Normal people and to executive, memory, and sustained attention deficits, formal thought disorders, and psychopathology in schizophrenia patients. Neurotox Res. https://​doi.​org/​10.​1007/​s12640-018-9937-8. [Epub ahead of print] PubMed PMID: 30056534.
Zurück zum Zitat Sum MY, Tay KH, Sengupta S, Sim K (2018) Neurocognitive functioning and quality of life in patients with and without deficit syndrome of schizophrenia. Psychiatry Res 263:54–60CrossRef Sum MY, Tay KH, Sengupta S, Sim K (2018) Neurocognitive functioning and quality of life in patients with and without deficit syndrome of schizophrenia. Psychiatry Res 263:54–60CrossRef
Zurück zum Zitat Smith RS, Maes M (1995) The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 45(2):135–141. PubMed PMID: 8531836. Smith RS, Maes M (1995) The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 45(2):135–141. PubMed PMID: 8531836.
Zurück zum Zitat Tamminga CA, Buchanan RW, Gold JM (1998) The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 13:s21–s26CrossRef Tamminga CA, Buchanan RW, Gold JM (1998) The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 13:s21–s26CrossRef
Zurück zum Zitat Tolman AW, Kurtz MM (2012) Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull 38(2):304–315. https://doi.org/10.1093/schbul/sbq077. Epub 2010 Jul 11. PubMed PMID: 20624752; PubMed Central PMCID: PMC3283161. Tolman AW, Kurtz MM (2012) Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull 38(2):304–315. https://​doi.​org/​10.​1093/​schbul/​sbq077. Epub 2010 Jul 11. PubMed PMID: 20624752; PubMed Central PMCID: PMC3283161.
Zurück zum Zitat Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A (1994) The consortium to establish a registry for Alzheimer's disease (CERAD). Part V. a normative study of the neuropsychological battery. Neurology 44(4):609–614CrossRef Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A (1994) The consortium to establish a registry for Alzheimer's disease (CERAD). Part V. a normative study of the neuropsychological battery. Neurology 44(4):609–614CrossRef
Zurück zum Zitat WHO (1993) Study protocol for the World Health Organization project to develop a quality of life assessment instrument (WHOQOL). Qual Life Res 2(2):153–159CrossRef WHO (1993) Study protocol for the World Health Organization project to develop a quality of life assessment instrument (WHOQOL). Qual Life Res 2(2):153–159CrossRef
Zurück zum Zitat Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG (2002) A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J Psychosom Res 52:501–509CrossRef Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG (2002) A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J Psychosom Res 52:501–509CrossRef
Metadaten
Titel
Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia
verfasst von
Buranee Kanchanatawan
Sira Sriswasdi
Michael Maes
Publikationsdatum
22.11.2018
Verlag
Springer US
Erschienen in
Metabolic Brain Disease / Ausgabe 1/2019
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-018-0339-7

Weitere Artikel der Ausgabe 1/2019

Metabolic Brain Disease 1/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.